Homozygous Deletions and Recurrent Amplifications Implicate New Genes Involved in Prostate Cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Prostate cancer cell lines provide ideal in vitro systems for the identification and analysis of prostate tumor suppressors and oncogenes. A detailed characterization of the architecture of prostate cancer cell line genomes would facilitate the study of precise roles of various genes in prostate tumorigenesis in general. To contribute to such a characterization, we used the GeneChip 500K single nucleotide polymorphic (SNP) array for analysis of genotypes and relative DNA copy number changes across the genome of 11 cell lines derived from both normal and cancerous prostate tissues. For comparison purposes, we also examined the alterations observed in the cell lines in tumor/normal pairs of clinical samples from 72 patients. Along with genome-wide maps of DNA copy number changes and loss of heterozygosity for these cell lines, we report previously unreported homozygous deletions and recurrent amplifications in prostate cancers in this study. The homozygous deletions affected a number of biologically important genes, including PPP2R2A and BNIP3L identified in this study and CDKN2A/CDKN2B reported previously. Although most amplified genomic regions tended to be large, amplifications at 8q24.21 were of particular interest because the affected regions are relatively small, are found in multiple cell lines, are located near MYC, an oncogene strongly implicated in prostate tumorigenesis, and are known to harbor SNPs that are associated with inherited susceptibility for prostate cancer. The genomic alterations revealed in this study provide an important catalog of positional information relevant to efforts aimed at deciphering the molecular genetic basis of prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24
Zanke, B. W., Greenwood, C. M., Rangrej, J., Kustra, R., Tenesa, A., Farrington, S. M., Prendergast, J., Olschwang, S., Chiang, T., Crowdy, E., et al. (2007) · Nature Genetics · doi:10.1038/ng2089 · Cited by 724 · cited 2×
“[38] Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM,”
BackgroundSpectral karyotype (SKY) analysis of human prostate carcinoma cell lines
van Bokhoven, A., Caires, A., Maria, M. D., Schulte, A. P., Lucia, M. S., Nordeen, S. K., Miller, G. J., & Varella‐Garcia, M. (2003) · The Prostate · doi:10.1002/pros.10291 · Cited by 56
Cited by
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Germline Mutations in HOXB13 and Prostate-Cancer Risk
Ewing, C. M., Ray, A. M., Lange, E. M., Zuhlke, K. A., Robbins, C. M., Tembe, W. D., Wiley, K. E., Isaacs, S. D., Johng, D., Wang, Y., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110000 · Cited by 658
Self-citationMechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Myung, J.-K., Banuelos, C. A., Fernandez, J. G., Mawji, N. R., Wang, J., Tien, A. H., Yang, Y. C., Tavakoli, I., Haile, S., Watt, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66398 · Cited by 305
The complexity of prostate cancer: genomic alterations and heterogeneity
Boyd, L. K., Mao, X., & Lu, Y.-J. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.185 · Cited by 214
Meyer, K. B., Maia, A.-T., O'Reilly, M., Ghoussaini, M., Prathalingam, R., Porter-Gill, P., Ambs, S., Prokunina-Olsson, L., Carroll, J., & Ponder, B. A. J. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002165 · Cited by 162
“The 3C experiments were carried out in the normal-like cell lines HB2 and RWPE-1 as many cancer cell lines such as PC3 and MCF-7 carry amplifications across the 8q24 region [9,10].”
BackgroundMethodNon-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
Kauko, O., & Westermarck, J. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.005 · Cited by 111
Meeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
“This can occur through promoter hypermethylation (53, 54), heterozygous deletion or chromosomal loss (55-58), loss-of-heterozygosity (44), homozygous deletion (46, 56-59), microRNA expression (60, 61), or through as yet undefined mechanisms (e.”
BackgroundCheng, Y., Liu, W., Kim, S.-T., Sun, J., Lu, L., Sun, J., Zheng, S. L., Isaacs, W. B., & Xu, J. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.05.002 · Cited by 64
“2 was found to be associated with PCa in our previous study (12), in which this HD was found in the PCa cell line VCaP and 1 out of 72 clinical PCa samples.”
BackgroundMethodSelf-citation
Metadata
- Authors
- Liu, W., Xie, C. C., Zhu, Y., Li, T., Sun, J., Cheng, Y., Ewing, C. M., Dalrymple, S., Turner, A. R., Sun, J., Isascs, J. T., Chang, B.-L., Zheng, S. L., Isaacs, W. B., & Xu, J.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 10
- Issue
- 8
- Pages
- 897-IN37
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W1547654062
- Cited by
- 126
- References
- 3
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.